Drug
Fluoroestradiol f-18 clinical trials
Also written F-18 FES.
Keep track of what changes. Save the fluoroestradiol f-18 studies recruiting or about to start, and get an email each week — studies that open, close, add sites or post results.
Watch these studiesHow studies write it
Studies that test it under each name
Studies by the year they started
9 studies that test it; most in 2021 (2)
| Year | Studies |
|---|---|
| 2010 | 1 |
| 2015 | 1 |
| 2016 | 1 |
| 2020 | 1 |
| 2021 | 2 |
| 2022 | 1 |
| 2024 | 1 |
| 2026 | 1 |
By phase
A phase 1/2 study counts in both.
What it is tested for
Each study’s main condition, where its own words name it.
Who runs them
Industry 0 · Other 9
University of Washington (2) · National Cancer Institute (NCI) (1) · Amsterdam UMC, location VUmc (1) · University of North Carolina, Chapel Hill (1) · City of Hope Medical Center (1) · Università Vita-Salute San Raffaele (1) · Vanderbilt-Ingram Cancer Center (1) · Annie (Annie) T. Packard (1)
Often tested with
Tested in the same studies.
Studies
Open first, then newest update. How each study uses fluoroestradiol f-18 is read from its arms, and is right about nine times in ten.
Testing it · 9
- Stereotactic Body Radiation Therapy and FES PET/CT Imaging for the Treatment of Oligoprogressive Estrogen Receptor Positive Metastatic Breast CancerRecruitingPhase 2City of Hope Medical CenterNCT06260033Written as F-18 16 Alpha-Fluoroestradiol
- 18F FES-PET/MRI for Tailoring Treatment of Luminal A and Lobular Breast CancerRecruitingPhase 2Università Vita-Salute San RaffaeleNCT05982496Written as FES
- Serial FES PET/CT to Measure Hormone Expression in Patients Undergoing Endocrine Targeted TherapyActive, not recruitingPhase 2University of WashingtonNCT04692103Written as F-18 16 Alpha-Fluoroestradiol
- FES PET/CT in Predicting Response in Patients With Newly Diagnosed Metastatic Breast Cancer Receiving Endocrine TherapyActive, not recruitingPhase 2National Cancer Institute (NCI)NCT02398773Written as F-18 16 Alpha-Fluoroestradiol
- Dynamic and Test-retest Whole Body [18F]FES PET Imaging in Patients With Metastatic ER+ Breast CancerActive, not recruitingNot applicableAmsterdam UMC, location VUmcNCT05088785Written as FES
- Evaluating Endometriosis With 16α-(18)F-fluoro-17β-estradiol ([F-18] FES) PET/MRIWithdrawnPhase 1/2Annie (Annie) T. PackardNCT04347135Written as F-18 FES
- Evaluation of Endometriosis With 18F-fluoroestradiol PET / MRICompletedPhase 2University of North Carolina, Chapel HillNCT04382911Written as 18F-fluoroestradiol
- F-18 FES PET/CT in Measuring Hormone Expression in Patients With Primary, Recurrent, or Metastatic Breast Cancer Undergoing Endocrine-Targeted TherapyTerminatedNot applicableUniversity of WashingtonNCT02149173Written as F-18 16 Alpha-Fluoroestradiol
- 18F-FES PET/CT in Imaging Patients With Desmoid TumorsTerminatedEarly Phase 1Vanderbilt-Ingram Cancer CenterNCT02374931Written as F-18 16 Alpha-Fluoroestradiol
Given in every arm · 1 — fluoroestradiol f-18 is usual care beside what is tested
Codes
What other systems call fluoroestradiol f-18 · ClinicalTrials.gg INT003175
- UNII (FDA) T32277KB09FLUOROESTRADIOL F-18Confirmed FDA, Wikidata
- RxNorm 2372221One source FDA
- Wikidata Q27289599fluoroestradiol f-18Confirmed FDA, Wikidata
- DrugBank DB15690One source Wikidata
| System | Code | Name there | Checked by |
|---|---|---|---|
| UNII (FDA) | T32277KB09 | FLUOROESTRADIOL F-18 | Confirmed FDA, Wikidata |
| RxNorm | 2372221 | — | One source FDA |
| Wikidata | Q27289599 | fluoroestradiol f-18 | Confirmed FDA, Wikidata |
| DrugBank | DB15690 | — | One source Wikidata |
“Confirmed” means two independent publishers link the code to this drug; “one source”, one does and its name agrees.